Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)
- 191 Downloads
Chromosomal translocations involving the anaplastic lymphoma kinase gene (ALK) are rare oncogenic events found in 3–5% of non-small-cell lung cancers (NSCLC). Limited data have been published on the management of these patients outside clinical trials.
To investigate the clinical characteristics and management of patients with NSCLC harboring ALK translocations (ALK+) in a real-life setting in France.
This multicenter, observational, retrospective study included all NSCLC patients harboring ALK translocations diagnosed in participating centers between January 2012 and December 2014. Patient data include clinical characteristics, disease management, and outcomes [progression-free survival (PFS) and overall survival (OS)].
The 31 participating centers reported data on 132 patients, of whom 51% (n = 67) were male. The median age was 60.1 ± 14.5 (standard deviation) years; 89% (n = 106/119) had performance status 0/1 at diagnosis; 79% (n = 103/130) were non- or former smokers; 93% (n = 120/129) had adenocarcinomas and 74%(n = 97)/19%(n = 25)/7%(n = 10) had disease stages IV/III/I-II at diagnosis, respectively; co-mutations included EGFR (n = 2), BRAF (n = 2), KRAS (n = 1), and HER2 (n = 1). Of the patients with stage IV NSCLC (n = 97), 96% received first-line treatment [75% chemotherapy-based, 21% ALK tyrosine kinase inhibitor (TKI)], with an associated response rate (RR), disease-control rate (DCR), and PFS of 42%, 64%, and 7.5 [95% confidence interval (CI) 5.9–9.5] months, respectively; 62% received second-line treatment (28% chemotherapy, 72% ALK TKI) with an associated RR, DCR, and PFS of 43.4%, 70%, and 4.7 (95% CI 4.0–8.1) months, respectively. The 2-year OS was 56.7% (95% CI 45.5–70.4%); median OS was not reached.
Compliance with Ethical Standards
The study was supported by academic grants from Lilly, Astra Zeneca, and Boehringer Ingelheim. The sponsors played no role in the design or performance of the study, data analysis, or manuscript preparation. The results belong to Groupe Français d’Oncologie Thoracique (GFPC). The data were analyzed by the GFPC statistician and interpreted by the authors.
Conflict of Interest
Jean-Bernard Auliac has received honoraria for attending scientific meetings, speaking, organizing research, or consulting from Boehringer Ingelheim, Hoffman-Roche, Lilly, and Pfizer. Helene Doubre has received honoraria for consulting from Novartis, AstraZeneca, BMS, MSD, and Boehringer Ingelheim. Christos Chouaid has received honoraria for attending scientific meetings, speaking, organizing research, or consulting from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffman-Roche, Sanofi Aventis, Lilly, Novartis, and Amgen. All other authors declare no conflict of interest.
- 1.World Health Organization (WHO). Cancer. Fact sheet no. 297. http://www.who.int/mediacentre/factsheets/fs297/en/.
- 2.Barlesi F, Mazières J, Merlio JP, et al. Biomarkers France contributors. Routine molecular profiling of patients with advanced non–small-cell lung cancer: Results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT). Lancet. 2016;387:1415–26.CrossRefPubMedGoogle Scholar
- 8.Gridelli C, de Marinis F, Cappuzzo F, et al. Treatment of advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: Results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2014;15:173–81.CrossRefPubMedGoogle Scholar
- 16.Duruisseaux M, Besse B, Cadranel J, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8(13):21903–17.Google Scholar